Waldencast PLC (NASDAQ:WALD) Short Interest Update

Waldencast PLC (NASDAQ:WALD) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 801,939 shares, a decrease of 39.6% from the December 15th total of 1,326,877 shares. Based on an average trading volume of 73,685 shares, the short-interest ratio is currently 10.9 days. Based on an average trading volume of 73,685 shares, the short-interest ratio is currently 10.9 days.

Analyst Ratings Changes

WALD has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Waldencast in a research report on Wednesday, October 8th. Telsey Advisory Group lowered shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price objective on the stock. in a report on Tuesday, November 25th. Jefferies Financial Group assumed coverage on shares of Waldencast in a research note on Wednesday. They set a “buy” rating and a $2.00 target price for the company. Finally, Canaccord Genuity Group dropped their price target on shares of Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.42.

Waldencast Price Performance

WALD traded down $0.03 during mid-day trading on Friday, hitting $1.62. 16,674 shares of the stock were exchanged, compared to its average volume of 60,008. The firm’s fifty day moving average is $2.03 and its two-hundred day moving average is $1.99. Waldencast has a 1-year low of $1.45 and a 1-year high of $4.10. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.53 and a quick ratio of 0.67.

Waldencast (NASDAQ:WALD) last issued its quarterly earnings results on Monday, November 24th. The company reported ($0.69) earnings per share (EPS) for the quarter. The firm had revenue of $66.14 million for the quarter. As a group, sell-side analysts expect that Waldencast will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Waldencast

Large investors have recently modified their holdings of the stock. Milestones Administradora de Recursos Ltda. raised its stake in shares of Waldencast by 10.3% in the third quarter. Milestones Administradora de Recursos Ltda. now owns 2,425,677 shares of the company’s stock valued at $4,803,000 after acquiring an additional 225,677 shares in the last quarter. UBS Group AG increased its holdings in Waldencast by 466.2% during the 3rd quarter. UBS Group AG now owns 838,536 shares of the company’s stock worth $1,660,000 after purchasing an additional 690,441 shares during the period. Geode Capital Management LLC raised its position in Waldencast by 62.2% in the 2nd quarter. Geode Capital Management LLC now owns 586,566 shares of the company’s stock valued at $1,437,000 after purchasing an additional 224,905 shares in the last quarter. McAdam LLC grew its position in shares of Waldencast by 174.6% during the third quarter. McAdam LLC now owns 63,014 shares of the company’s stock worth $125,000 after buying an additional 40,063 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Waldencast by 15.2% in the first quarter. Rhumbline Advisers now owns 61,630 shares of the company’s stock valued at $185,000 after buying an additional 8,151 shares during the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.